Table 1. Baseline socio-demographic and clinical characteristics and engagement in computerised cognitive–behavioural therapy programme.
| Characteristics | African American participants (N=91) | White participants (N=499) | P | Adjusted P |
|---|---|---|---|---|
| Age, mean (s.d.) | 39.9 (13.9) | 43.6 (14.2) | 0.02 | NA |
| Male, n (%) | 12 (13) | 110 (22) | 0.05 | NA |
| High school diploma or higher, n (%) | 70 (77) | 414 (83) | 0.17 | NA |
| Mental health diagnosis | 0.97 | NA | ||
| Depression only, n (%) | 38 (42) | 205 (41) | ||
| Anxiety only, n (%) | 6 (7) | 45 (9) | ||
| Depression and anxiety, n (%) | 45 (49) | 235 (47) | ||
| PHQ-9,a mean (s.d.) | 14.4 (4.5) | 13.1 (5.0) | 0.01 | NA |
| GAD-7,b mean (s.d.) | 13.2 (4.1) | 12.8 (4.4) | 0.63 | NA |
| Pharmacotherapy use, n (%) | 69 (76) | 449 (90) | <0.001 | NA |
| Started first session, n (%) | 68 (75) | 432 (87) | 0.01 | 0.01 |
| Completed all eight sessions, n (%) | 20 (29) | 186 (43) | 0.03 | 0.09 |
| Sessions completed, mean (s.d.) | ||||
| ≤3 months | 4.2 (2.8) | 4.8 (2.5) | 0.08 | 0.10 |
| ≤6 months | 4.7 (2.7) | 5.5 (2.7) | 0.03 | 0.07 |
PHQ-9 and GAD-7 scores were assessed by research assistants, blinded to patient randomisation status, over the telephone at baseline. The baseline assessor-administered PHQ-9 scores were highly correlated with self-entered PHQ-9 scores at session 1 (r=0.53; P<0.01). Race was self-reported. Primary Care Evaluation of Mental Disorders (PRIME-MD) was used to evaluate depression and anxiety diagnosis. Adjusted models controlled for age, gender, education, PHQ-9 and baseline pharmacotherapy use.
a
PHQ-9=Patient Health Questionnaire 9-item Scale, assessor-administered.
b
GAD-7=Generalised Anxiety Disorder 7-item Scale, assessor-administered.